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Right atrial papillary
fibroelastoma associated with
atrial septal defect, persistent
superior vena cava, and
coronary artery disease
To the Editor:
We read with interest the article by Lauten
and coworkers1 regarding the successful re-
section of a right atrial papillary fibroelas-
toma (PF). We have additional surgical
experience with this infrequent location of
the neoplasm.
A 60-year-old man with a history of arte-
rial hypertension and a transient ischemic
attack underwent a transthoracic echocardio-
gram, which demonstrated a mass inside the
right atrium (RA). Further cardiologic evalua-
tion including transesophageal echocardio-
gram and complete cardiac catheterization
and coronary arteriography disclosed a tumor
in the RA, fenestrated atrial septal defect
(ASD), persistent left superior vena cava
(LSVC), and severe coronary artery disease
with tight stenosis in the proximal left anterior
descending coronary artery (LAD) and mid-
dle right coronary artery (RCA).The patient
underwent surgery on June 6, 1998. A median
sternotomy was performed. Under standard
cardiopulmonary bypass, with cannulation
of the aorta, both venae cavae, and the
LSVC, the aorta was crossclamped. Intermit-
tent cold blood cardioplegia was administered
and the three venae cavae were snared. A right
atriotomy was performed, a 231.5-cm gelat-
inous tumor attached to the muscular endocar-
dium of the RA was completely removed, an
ostium secundum type of ASD was closed
with an autologous pericardial patch, and
a double coronary bypass graft to the LAD
and RCA was carried out. The patient had
an uncomplicated surgery and recovery and
was discharged home 10 days after the oper-
ation. Gross and histologic examination of
the mass was typical of PF. At present, 9 years
6 months after the operation, the patient re-
mains asymptomatic. A recent transthoracic
echocardiogram showed no intracavitary
masses, closure of the interatrial septum, and
normal left ventricular function.
PF is an endocardial tumor that repre-
sents the second or third most common car-
diac neoplasm, accounting for less than 10%
of all primary benign heart tumors. It is most
frequent in the left side of the heart and gen-
erally develops in the heart valves; however,
other endocardial heart locations have also
been described. Right PF arising from the
nontricuspid valve or interatrial septum is
extremely uncommon. We only found
a few surgically treated patients.1-7 To the
best of our knowledge, excision of a free-
wall PF in association with closure of an
ASD and coronary artery bypass grafting
has not been previously reported.
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To the Editor:
I read with great interest the article by Ber-
trand Marcheix and associates.1 I congratu-ascular Surgery c August 2008late them for this well-designed study, but I
also wish to add some brief comments. The
aim was to determine the impact of less-in-
vasive techniques for treatment of high-
risk patients with aortic valve disease by
using a self-expandable aortic bioprosthesis
(CoreValve Inc, Paris, France) suitable for
percutaneous retrograde delivery. The
mean logistic EuroSCORE was 32%. Of
10 patients undergoing successful implants,
2 died within 30 days and a third died later,
for an overall 30% hospital mortality. Vas-
cular complications were observed in 5 pa-
tients. Mean intensive care unit stay was
4.6 days and hospital stay was 15 days.
The authors concluded that the technique
is a viable alternative in selected high-risk
patients.
With the aim of reducing surgical inva-
siveness, epidural anesthesia, maintaining
an autonomic ventilation, has been sug-
gested,2 and the outcomes of 30 consecutive
patients who underwent epidural awake aor-
tic valve surgery (47% female, mean age
78.1% 6 8, 20% multivessel coronary dis-
ease, mean Logistic-EuroScore 28.3) have
been presented at the European Association
for Cardio-thoracic Surgery meeting in
Geneva. One patient had a redo operation.
Associated surgical procedures included
coronary artery bypass grafting (17%), as-
cending aorta replacement (10%), mitral
valve surgery (10%), and pulmonary vein
isolation to treat atrial fibrillation. Unless
emergency, no other exclusion criteria
were considered. One patient died, for an
operative mortality of 3%, and 2 patients
died during the follow-up period (natural
death). All other complications occurred
rarely (stroke, no cases; bowel ischemia,
no cases; prolonged mechanical ventilation,
2 cases; myocardial infarction, 1 case). Me-
dian stays in the ward and the intensive care
unit were 4.5 days and 1 day, respectively.
Seven patients have been transferred to the
ward within 3 hours after surgery and 19
patients in 12 hours or less.
The goal of aortic valve stenosis treat-
ment is to achieve a complete regression of
symptoms while offering the lowest mor-
bidity and mortality. The main reason that
percutaneous interventions are more accept-
able to the patients is the simplicity. Unfor-
tunately, interventional cardiologists and
cardiac surgeons are going to rethink the
management of high-risk aortic stenosis1,3,4
without a well-founded clinical program
and forgetting the patients’ and economic
Letters to the Editorcommunity interests. For instance, in the se-
ries reported by Webb and colleagues,4 72%
had coronary artery disease. No data de-
scribe how these patients have been man-
aged. Furthermore, a long series of
exclusion criteria precluded the percutane-
ous aortic valve implantation in this and
other series,3,4 although the implantation
of a percutaneous prosthesis is initially con-
sidered in patients with absolute surgical
contraindications. Nevertheless, in the expe-
rience reported by Webb and associates,4
a patient had been successfully converted
to surgery. By using epidural anesthesia,
my colleagues and I2 did not add any cost,
and we greatly reduced the need for inten-
sive care unit management. On the other
hand, considering that the percutaneous
prostheses are sold at a cost 10-fold higher
than a standard bioprostheses, and consider-
ing the early 30-day results of percutaneous
implantation,1,3,4 we maintain that surgeryNotice of Correction
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taneous approach. On the contrary, we be-
lieve that currently there are no factors that
might preclude surgery for any patient. In-
stead of finding a way to replace surgical
therapy, percutaneous approaches should
be used as an adjunct to surgery, to support
it in its current limitations, such as being
used to replace deteriorating bioprostheses
and avoiding the complications related to
repeated heart dissections.5
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